Prostate News and Research

RSS

Nation-wide study to assess risk of suicide among men

The introduction of prostate-specific antigen (PSA) testing as a screening tool for early detection of prostate cancer (PCa) in the beginning of the 1990s drastically increased the detection of PCa. The risk of suicide is increased among cancer patients including men with PCa.

23 Feb 2010

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

The National Basketball Association's (NBA) Denver Nuggets Coach George Karl announced today that he has been diagnosed with treatable neck and throat cancer. According to published media reports, Karl's physician says the coach has cancer of his right tonsil that has spread to a lymph node in his neck. The 58-year-old Karl, who is also a prostate cancer survivor, coached in the NBA's All-Star game this past weekend.

22 Feb 2010

Racial disparities in beliefs about lung cancer

A new survey has found that African-Americans are more likely than whites to hold mistaken and fatalistic beliefs about lung cancer, as well as being more reluctant to consult a doctor about possible symptoms of the disease, according to researchers from Dana-Farber Cancer Institute and their collaborators.

22 Feb 2010

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

Of the 200,000 men newly diagnosed with prostate cancer each year in the United States, about one-third will undergo surgical treatment. Although open radical prostatectomy (ORP) is regarded as the standard treatment, laparoscopic radical prostatectomy (LRP) with or without robotic assistance is becoming more common.

22 Feb 2010

Researchers develop new tool to understand how cancer grows

Researchers have a new tool to understand how cancers grow -- and with it a new opportunity to identify novel cancer drugs. They've been able to break apart human prostate tissue, extract the stem cells in that tissue, and alter those cells genetically so that they spur cancer.

22 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

US scientists develop new technique to track the progression of cancer

US scientists have developed a new technique that allows them to track the progression of a person's cancer by uncovering changes in their tumour's genetic material.

19 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

Most genetic abnormalities shared across multiple cancers

An international team of researchers has created a genome-scale map of 26 different cancers, revealing more than 100 genomic sites where DNA from tumors is either missing or abnormally duplicated compared to normal tissues. The study, the largest of its kind, finds that most of these genetic abnormalities are not unique to one form of cancer, but are shared across multiple cancers. The work appears in the February 18 issue of the journal Nature.

19 Feb 2010

11 cities to join DASH FOR DAD national race series to end prostate cancer

DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.

19 Feb 2010

Roseville ROC commences cancer treatment with Elekta VMAT

The first treatments with Elekta Volumetric Modulated Arc Therapy (VMAT) began November 17, 2009 at Roseville Radiation Oncology Center (ROC) at Radiological Associates of Sacramento (RAS). RAS, a large private medical group, includes diagnostics as well as therapy in its centers. ROC treats 30-35 patients per day, mainly with prostate and breast lesions.

From Elekta 19 Feb 2010

Researcher develops acoustic resonant sensor that can test bodily fluids for variety of diseases

What if it were possible to go to the store and buy a kit to quickly and accurately diagnose cancer, similar to a pregnancy test? A University of Missouri researcher is developing a tiny sensor, known as an acoustic resonant sensor, that is smaller than a human hair and could test bodily fluids for a variety of diseases, including breast and prostate cancers.

18 Feb 2010

Researchers discover new prognosis marker for prostate cancer

Measuring levels of the active form of the protein EGFR in the tumor and its vicinity can provide a more reliable prognosis for individuals with prostate cancer.

18 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

Olympus launches new medical devices for LESS surgery

A variety of new medical devices specifically designed for Laparo-Endoscopic Single-Site surgery (LESS surgery) has been announced and introduced by Olympus Europa Holding GmbH and Olympus Medical Systems Corporation. LESS surgery is an advanced, minimally invasive operation technique by which an endoscope and hand instruments are inserted through an access port anchored in just one small incision, usually made in the navel. After developing all the medical devices needed to perform LESS surgery, Olympus has yet again proven its leadership in the field. The release of these innovative devices in Europe took place in autumn 2009.

From Evident Corporation - Life Sciences 18 Feb 2010

Northern California Cancer Center becomes Cancer Prevention Institute of California

As the only organization in the country dedicated solely to cancer prevention research, the Northern California Cancer Center has changed its name to the Cancer Prevention Institute of California. The new name immediately communicates the organization's critical mission to prevent cancer and reflects its service to the entire state of California.

18 Feb 2010

Patients and doctors differ when it comes to daily health activities

When it comes to daily health activities such as diet and exercise, Americans and their doctors may not always see eye to eye.

17 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

The first ever actuarial analysis of lung cancer mortality, published today in Population Health Management Journal, provides strong evidence that earlier detection could reduce the number of late stage lung cancer deaths by over 70,000 people each year in the US.

17 Feb 2010

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.”

17 Feb 2010

Prostate News and Research

Nation-wide study to assess risk of suicide among men

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

Racial disparities in beliefs about lung cancer

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

Researchers develop new tool to understand how cancer grows

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

US scientists develop new technique to track the progression of cancer

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

Most genetic abnormalities shared across multiple cancers

11 cities to join DASH FOR DAD national race series to end prostate cancer

Roseville ROC commences cancer treatment with Elekta VMAT

Researcher develops acoustic resonant sensor that can test bodily fluids for variety of diseases

Researchers discover new prognosis marker for prostate cancer

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Olympus launches new medical devices for LESS surgery

Northern California Cancer Center becomes Cancer Prevention Institute of California

Patients and doctors differ when it comes to daily health activities

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News